C-JSCELinkGevity
Anti-Necrotics, necrosis inhibition, AI Blueprint Maps
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-JSCE
C-JSCEC-JSCEAnti-Necrotics, necrosis inhibition, AI Blueprint Maps
0-100 chain-logic scale · 15 dimensions · scored on public evidence
LinkGevity Anti-Necrotics, necrosis inhibition, AI Blueprint Maps
LinkGevity is focused on longevity science, extending healthspan through AI-driven drug discovery and its proprietary Blueprint Theory. The company builds Blueprint Maps to identify triggers of aging and age-related disease. Its Anti-Necrotics are described as first-in-class necrosis inhibitors, with clinical and non-clinical programs spanning kidney disease, ageing, tissue engineering, organ preservation, and related applications.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
LinkGevity — Translational · Bottom quartile. Derived deterministically from 23 extracted project(s). Most-advanced status: phase 2. Band: translational. Modifiers: +5 depth (2 programs at…
Source: Deterministic